Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome. (UX007)

This is a single-center, exploratory, open-label study in 10 girls diagnosed with Rett Syndrome. The study will consist of the following 4 parts: Screening/Baseline run-in, Titration/Dose-Setting, Treatment, and Washout/Follow-up.

Study Overview

• Status: Unknown
• Conditions: Rett Syndrome
• Intervention / Treatment: Drug: Tridecanoic Acid

Detailed Description

1. Screening and baseline assessments (4 weeks before first treatment): After having the parents sign an informed consent, eligible patients will undergo baseline assessments (safety and disease variables) as follows:

   • Physical examination
   • Vital signs: sitting Blood Presure (BP),Heart Rate (HR) and respiratory rate, arm pit temperature.
   • Baseline height and weight parameters
   • ECG (ElectroCardioGraphy)
   • 3-hour video EEG (ElectroEncephaloGram)
   • 24-hour NOX-T3 (Portable Sleep Monitor) recording
   • QOL (Quality of Life) and Rett Syndrome-specific functional/severity questionnaires
   • Laboratory blood tests, including endocrinology, hematology, and biochemistry.
   • Parents will be requested to fill in a diary and record on a daily basis seizure occurrence for at least 4 weeks before first treatment. In addition they will be asked to record their top 3 concerns pertaining to the care and overall well-being of the patient.

2. Treatment period (20 weeks):

   1. Initial and final dose setting (2 weeks): UX007 will be titrated in each patient over 2 weeks to a dose of 1-4 grams per kilogram per day (based on age). If a subject cannot tolerate titrating up to the 1-4 g/kg/day dose level, the dose should be titrated to the maximum tolerated dose as determined by the Investigator. At the end of the Titration Period, the subject will be maintained on the maximum UX007 dose achieved during the Titration Period for the duration of the study.

      The following assessments will be performed:

      • QOL and RTT-specific functional/severity questionnaires

   2. Final dose (18 weeks): Patients will receive a dose of UX007 as determined in the Titration/Dose Setting period. They will be followed up by the Investigator and undergo safety and disease-related assessments as follows (schedules outlined in the protocol):

      • Physical examination
      • Vital signs (sitting BP, HR and respiratory rate, oral temperature)
      • Height and weight parameters
      • ECG
      • 3-hour video EEG
      • 24-hour NOX recording
      • Motor assessment
      • QOL and RTT-specific functional/severity questionnaires
      • Laboratory blood tests, including endocrinology, hematology, and biochemistry.
      • Data collection from parents' diaries

4. Post-Washout Follow-up/End-of-Study:

Within approximately six (6) weeks after last dose administration, a termination visit will be scheduled. The following activities will take place:

• Physical examination
• Vital signs (sitting BP, HR and respiratory rate, oral temperature)
• Height and weight parameters
• ECG
• 3-hour video EEG
• 24-hour NOX recording
• Motor assessment
• QOL and RTT-specific functional/severity questionnaires
• Laboratory blood tests, including endocrinology, hematology, and biochemistry.
• Data collection from parent's diaries
• Decision regarding continued administration of UX007 to patients who benefitted from the trial after the dechallenge period

• Study Type: Interventional
• Enrollment (Anticipated): 10
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Bruria Ben-Zeev, MD; Phone Number: 97235302687; Email: bruria.benzeev@sheba.health.gov.il
• Study Contact Backup: Name: Andreea Nissenkorn, MD; Phone Number: 97235302687; Email: andreea.nissenkorn@sheba.health.gov.il

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 5 years to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Female patients aged 5 to18 years (inclusive).
• A classical diagnosis of RTT, defined according to the internationally agreed 2010 Rett Search criteria, and with MECP2 pathogenic mutation.

• Patients with one or both of the following:

  • At least 2 seizures per month as per history during the four-week baseline period according to parent diary or per 3 hours video EEG recording
  • Walking abilities, independent or with support
• Patients with breathing abnormalities as recorded by baseline NOX recording.

Exclusion Criteria:

• Patients with significant metabolic, liver, cardiac, or respiratory morbidity not related to RTT
• Patients with significant liver, cardiac or respiratory morbidity related to RTT

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: open label	Drug: Tridecanoic Acid; 3 times daily oral doze of the drug for 20 weeks with 4 weeks of baseline and 4 weeks of washout; Other Names: triheptanoin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The number of patients with adverse events.	The number of patients which will show adverse events during the screening, treatment and washout periods.	30 weeks
The number of patients with ECG changes	The number of patients that show ECG changes and the type of change during the screening, treatment and washout periods.	30 weeks
The number of patients with changes in vital signs.	The number of patients which will show change in vital signs during the screening, treatment and washout periods including bloodpressure, heart rate, respiration rate and body temperature.	30 weeks
The number of patients with changes in physical examination.	The number of patients who show a change in their physical examination during the screening, treatment and washout periods including height, neurological findings, change in size of liver and spleen , skin changes.	30 weeks
The number of patients with changes in BMI	The number of patients who will show change in BMI and its direction during the screening, treatment and washout periods.	30 weeks
The number of patients with changes in laboratory examination including hematology, biochemistry and endocrinological measurements	The number of patients who will show changes in laboratory examination including hematology, biochemistry and endocrinological measurements during the screening, treatment and washout periods.	30 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in seizure frequency during treatment with triheptanoin in Rett syndrome	The change in number of seizures in each patient from the base line period to the treatment period and washout period	30 weeks

Collaborators and Investigators

• Sponsor: Sheba Medical Center
• Collaborators: Ultragenyx Pharmaceutical Inc
• Investigators: Principal Investigator: Bruria Ben-Zeev, MD, Head of pediatric neurology unit in Sheba medical center

Study record dates

Study Major Dates

• Study Start (Anticipated): April 1, 2017
• Primary Completion (Anticipated): April 1, 2018
• Study Completion (Anticipated): August 1, 2018

Study Registration Dates

• First Submitted: February 2, 2017
• First Submitted That Met QC Criteria: February 16, 2017
• First Posted (Actual): February 23, 2017

Study Record Updates

• Last Update Posted (Actual): February 23, 2017
• Last Update Submitted That Met QC Criteria: February 16, 2017
• Last Verified: February 1, 2017

More Information

Terms related to this study

• Keywords: Rett syndrome, Triheptanoic acid, Walking, EEG
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Disease; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Mental Retardation, X-Linked; Intellectual Disability; Heredodegenerative Disorders, Nervous System; Syndrome; Rett Syndrome
• Other Study ID Numbers: 3027-16-SMC

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: the final results of the study will be shared with ultragenix pharmaceutical and with other RETT syndrome researchers

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No